CLSD Logo

Clearside Biomedical, Inc. (CLSD) 

NASDAQ
Market Cap
$76.6M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
118 of 774
Rank in Industry
77 of 432

Largest Insider Buys in Sector

CLSD Stock Price History Chart

CLSD Stock Performance

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. …

Insider Activity of Clearside Biomedical, Inc.

Over the last 12 months, insiders at Clearside Biomedical, Inc. have bought $849,309 and sold $39,372 worth of Clearside Biomedical, Inc. stock.

On average, over the past 5 years, insiders at Clearside Biomedical, Inc. have bought $611,175 and sold $697,766 worth of stock each year.

Highest buying activity among insiders over the last 12 months: WHITMORE BRADFORD T (10 percent owner) — $1.2M. Gibney Anthony S (director) — $129,665. Chong Ngai Hang Victor (CHIEF MEDICAL OFFICER) — $109,410.

The last purchase of 36,500 shares for transaction amount of $36,500 was made by Chong Ngai Hang Victor (Chief Medical Officer) on 2024‑11‑01.

List of Insider Buy and Sell Transactions, Clearside Biomedical, Inc.

2024-11-01PurchaseChief Medical Officer
36,500
0.0483%
$1.00$36,500+6.93%
2024-06-24PurchaseChief Medical Officer
23,500
0.0309%
$1.06$24,910+4.17%
2024-05-15Purchasedirector
7,813
0.0104%
$1.31$10,235-11.74%
2024-04-18Purchasedirector
93,290
0.123%
$1.30$121,277-9.02%
2024-04-17Purchasedirector
6,710
0.0089%
$1.25$8,388-3.20%
2024-03-20PurchaseCHIEF MEDICAL OFFICER
30,000
0.0394%
$1.60$48,000-23.93%
2024-02-07Purchase10 percent owner
444,444
0.7241%
$1.35$599,999-7.61%
2024-01-19SaleCEO
18,000
0.0286%
$1.27$22,8600.00%
2024-01-19SaleChief Financial Officer
12,900
0.0207%
$1.28$16,5120.00%
2023-11-01Purchase10 percent owner
64,366
0.101%
$0.74$47,901+63.83%
2023-10-31Purchase10 percent owner
70,812
0.1147%
$0.73$51,537+72.51%
2023-10-30Purchase10 percent owner
600
0.001%
$0.69$411+81.42%
2023-10-03Purchasedirector
10,000
0.0159%
$0.86$8,600+44.88%
2023-09-25Purchasedirector
10,000
0.0163%
$0.86$8,600+43.53%
2023-01-20SaleChief Medical Officer
13,700
0.0223%
$1.47$20,139-28.67%
2023-01-19SaleCEO
20,030
0.033%
$1.46$29,244-27.21%
2023-01-19SaleChief Financial Officer
14,030
0.0238%
$1.50$21,045-27.21%
2023-01-10SaleChief Medical Officer
2,170
0.0035%
$1.62$3,515-35.54%
2022-12-21Purchasedirector
14,000
0.0236%
$1.02$14,266+7.00%
2022-11-17Purchasedirector
30,000
0.0489%
$1.33$39,900-18.52%

Insider Historical Profitability

26.36%
WHITMORE BRADFORD T10 percent owner
4495034
5.9267%
$1.01113+79.94%
LASEZKAY GEORGE MCEO
466577
0.6152%
$1.01111+58.62%
Deignan Charles A.Chief Financial Officer
384662
0.5072%
$1.0147+20.35%
Gibney Anthony Sdirector
100000
0.1319%
$1.0120
Chong Ngai Hang VictorChief Medical Officer
100000
0.1319%
$1.0130

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Armistice Capital Llc$6.05M5.293.96MNew+$6.05M0.02
The Vanguard Group$3.81M3.332.49M+14.45%+$481,154.41<0.0001
Carmignac$3.26M2.852.13M0%+$00.05
BlackRock$1.16M1.02758,226-0.2%-$2,321.01<0.0001
Geode Capital Management$982,799.000.86642,213+30.88%+$231,880.47<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.